Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 472 participants.
Also called NCT07910058
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 472 participants
- Sponsor
- Registry
-
NCT07910058
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07910058. Randomized; single masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2029-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
- Acronym
- SUPERIOR 2
- Condition
- Atrial Fibrillation (Persistent)
- Condition
- Catheter Ablation
- Condition
- Non-hypertension
- Condition
- Angiotensin Receptor/Neprilysin Inhibitor
- Intervention (Drug)
- Sacubitril/Valsartan
- Intervention (Other)
- Standard Care
- Lead sponsor
- Ruijin Hospital
Record details
- Record id
cardio:ct-nct07910058- Content hash
1056ef74fed73281de7f0b8e0bb07fb44a47366e4645f6aed2af69b51dbc6ffb